





		<b>EMLc</b>	ATC codes: <b>J01DD02</b>
<b>Indication</b>	Pseudomonas aeruginosa resistant to other antibiotic	ICD11 code: <b>MG50.8Y</b>	
<b>INN</b>	Ceftazidime		
<b>Medicine type</b>	Chemical agent		
<b>Antibiotic groups</b>	 <b>WATCH</b>		
<b>List type</b>	Complementary (EML) (EMLc)		
<b>Formulations</b>	Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection ; 1 g in vial (as pentahydrate) powder for injection		
<b>EML status history</b>	First added in 1995 ( <a href="#">TRS 867</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
<b>Wikipedia</b>	<a href="#">Ceftazidime</a> 		
<b>DrugBank</b>	<a href="#">Ceftazidime</a> 		

## Summary of evidence and Expert Committee recommendations

Ceftazidime was included on the complementary list of the first EMLc in 2007.

